Screener Summaries Updates Institutions Sign In More Updates › Other Events › HCWB Other Events · Jun 16, 2026
HCW Biologics Inc. announced positive preliminary human data from the first two dose-escalating Phase 1 clinical trial… HCWB HCW Biologics Inc.
HCW Biologics Inc. announced positive preliminary human data from the first two dose-escalating Phase 1 clinical trial cohorts for HCW9302, an IL-2 based fusion immunotherapeutic targeting alopecia areata. HCW Biologics Inc. is a biotechnology company focused on developing fusion immunotherapeutics for autoimmune and inflammatory diseases.
More from HCW Biologics Inc. HCW Biologics closes $10M secured debt financing, including $3M upfront Nov 5, 2026 HCW Biologics Inc. entered into a Securities Purchase Agreement on September 23, 2026, to sell 903,614 units at… Sep 24, 2026 HCW Biologics Inc. entered into an Exclusive Distribution Agreement with Akron Biotech on September 4, 2026, for the… Sep 8, 2026 HCW Biologics Inc. reported financial results for the quarter ended June 30, 2026, including a net loss of $5.2… Aug 14, 2026 HCW Biologics Inc. announced on August 10, 2026, that its Audit Committee concluded previously issued unaudited… Aug 14, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
